High Court Refuses Pfizer Appeal Over Novartis Hemophilia IP

Law360, New York (April 16, 2012, 12:00 PM EDT) -- The U.S. Supreme Court on Monday declined to hear a Pfizer Inc. unit's argument that a lower court incorrectly upheld Novartis Vaccines & Diagnostics Inc.'s hemophilia drug patents based based on a related but later invention.

The high court refused to grant a petition for certiorari filed by Genetics Institute LLC — a former subsidiary of Wyeth, which was purchased by Pfizer in 2009 — in which the company sought to have overturned last year's Federal Circuit ruling holding that the two Novartis patents were nonobvious...
To view the full article, register now.